| Literature DB >> 26667010 |
D J Tomlinson1, R M Erskine1,2, C I Morse1, K Winwood1, Gladys Onambélé-Pearson3.
Abstract
Obesity is associated with functional limitations in muscle performance and increased likelihood of developing a functional disability such as mobility, strength, postural and dynamic balance limitations. The consensus is that obese individuals, regardless of age, have a greater absolute maximum muscle strength compared to non-obese persons, suggesting that increased adiposity acts as a chronic overload stimulus on the antigravity muscles (e.g., quadriceps and calf), thus increasing muscle size and strength. However, when maximum muscular strength is normalised to body mass, obese individuals appear weaker. This relative weakness may be caused by reduced mobility, neural adaptations and changes in muscle morphology. Discrepancies in the literature remain for maximal strength normalised to muscle mass (muscle quality) and can potentially be explained through accounting for the measurement protocol contributing to muscle strength capacity that need to be explored in more depth such as antagonist muscle co-activation, muscle architecture, a criterion valid measurement of muscle size and an accurate measurement of physical activity levels. Current evidence demonstrating the effect of obesity on muscle quality is limited. These factors not being recorded in some of the existing literature suggest a potential underestimation of muscle force either in terms of absolute force production or relative to muscle mass; thus the true effect of obesity upon skeletal muscle size, structure and function, including any interactions with ageing effects, remains to be elucidated.Entities:
Keywords: Ageing; Functional limitations; Muscle strength; Obesity; Sarcopenic obesity
Mesh:
Year: 2015 PMID: 26667010 PMCID: PMC4889641 DOI: 10.1007/s10522-015-9626-4
Source DB: PubMed Journal: Biogerontology ISSN: 1389-5729 Impact factor: 4.277
Fig. 1Representative DEXA scans taken from Tomlinson et al. (2014b) of a (i) young obese female versus young normal weight female and (ii) old obese female versus old normal weight female. Colour key: blue for bone, red for lean tissue, yellow for adipose tissue. (Color figure online)
Summarises research conducted into the effect of obesity on muscle strength in adolescence (14–17 years old)
| Studies | Gender | Samples (years) | Muscle group | Measures | Findings |
|---|---|---|---|---|---|
| Blimkie et al. ( | M | 11 Obese (16.5) | KE | – IM KE MVC 90°, 120°, 140°, 160° | – IM MVC all angles p = ns |
| Maffiuletti et al. ( | M | 10 Obese (15.6) | KE | – IM KE MVC 40°, 80° | – IM MVC 40° ↑ obese |
| Abdelmoula et al. ( | M | 12 Obese (14.2) | KE | – IM KE MVC 60° | – IM MVC ↑ obese |
M males, F females, KE knee extensor, IM isometric, IK isokinetic, CSA cross sectional area, MUA motor unit activation, BM body mass, LM lean mass, MM muscle mass, FFM fat free mass
Summarises research conducted into the effect of obesity on muscle strength through young to old adulthood (18–80 years old)
| Studies | Gender | Samples (years) | Muscle groups | Measures | Findings |
|---|---|---|---|---|---|
| Hulens et al. ( | F | 173 Obese (39.9) | – KE | – IK KE MVC 60°/s | – IK KE MVC 60°/s ↑ obese |
| Hulens et al. ( | F | 241 Obese (39.2) | – KE | – IK KE MVC 60°/s, 240°/s | – Y obese ↑ IK KE MVC 60°/s, 240°/s |
| Lafortuna et al. ( | M and F | 28 M Obese (29.2) | – Upper limb | – CP IT MVC | – M ↑ IT CP MVC |
| Maffiuletti et al. ( | M | 10 Obese (25.3) | – KE | – IM KE MVC 40°, 60°, 80° | – Obese ↑ IM MVC 40°, 60°, 80° |
| Hilton et al. ( | M and F | 6 Obese (58.0: 4 men, 2 women) | – PF | – PF and DF IM MVC 0° (neutral) | – ↓ Obese PF and DF IM MVC 0° |
| Lafortuna et al. ( | M and F | 21 M (50.5, range 31–71) | – Lower limb | – Lower limb MV using CT | – M MV versus adiposity r2 = 0.683; p < 0.001 |
| Tomlinson et al. ( | F | 54 Y (26.7) | – PF | – PF and DF IM MVC 0° | – ↑ Y obese PF and DF IM MVC 0° |
| Tomlinson et al. ( | F | 49 Y (25.5) | – PF | – GM IM PF MVC/MV | – ↓ Y obese GM IM PF MVC/MV |
| Tomlinson et al. ( | F | 52 Y (25.0) | – PF | – GM MV | – ↑ Y obese GM MV |
| Zoico et al. ( | F | 167 F (range 67–78) | – KE | – KE IM MVC | – KE IM MVC p = ns |
| Rolland et al. ( | F | 215 Obese (80.0) | – EE | – EE IM MVC | – Obese ↑ EE IM MVC (both NW and lean) |
M males, F females, NW normal weight, KE knee extensor, KF knee flexion, IM isometric, IK isokinetic, IT isotonic, CSA cross sectional area, MUA motor unit activation, BM body mass, LM lean mass, MM muscle mass, FFM fat free mass, TE trunk extension, TF trunk flexion, Y young, O old, CP chest press, LP leg press, IMAT intra muscular adipose tissue, MRI magnetic resonance imagery, CT computed tomography, MV muscle volume, sEMG surface electromyography, GM gastrocnemius medialis, PCSA physiological cross sectional area, Lf fascicle length, PA physical activity
Fig. 2Interplay between obesity, inflammation and skeletal muscle. Solid arrows denote events with established evidence. CRP C-reactive protein, HGF hepatocyte growth factor, IL-1β interleukin-1β, IL-6 interleukin-6, IL-8 interleukin-8, IL-10 interleukin-10, IL-1Ra interleukin-1 receptor antagonist, MCP-1, monocyte chemoattractant protein 1, MIF macrophage migration inhibitory factor, NGF nerve growth factor, PGE2 prostaglandin E2, SAA 1 and 2 serum amyloid A proteins 1 and 2, SV stromovascular, TGF-β1 transforming growth factor-β1, TNF-α tumor necrosis factor-α, VEGF vascular endothelial growth factor, IGF-1 insulin-like growth factor-1